53 results about "Vascular endothelial cell proliferation" patented technology

The invention relates to the field of pharmaceutical chemistry, and in particular to a lenalidomide derivative (I). G and n are defined in a direction book. Pharmacological tests show that the lenalidomide derivative plays an inhibiting role in vascular endothelial cell proliferation and can be used for clinical treatment of tumors or chronic inflammations.

The invention provides a human anti-vascular endothelial cell growth factor (VEGF) antibody as well as a coding gene and an application thereof. According to the invention, by virtue of genetic engineering means and a phage surface display technology, an anti-VEGF genetic engineering single-chain antibody is screened from a complete synthesis single-chain human antibody library, a variable region gene sequence of the anti-VEGF genetic engineering single-chain antibody is obtained, amino acids in a CDR (complementary determining region) of the anti-VEGF genetic engineering single-chain antibody are transformed by virtue of bioinformatics means, and finally a series of high-affinity anti-VEGF antibodies are obtained by constructing and screening mutation libraries and utilizing a chain exchange method, wherein affinity of the anti-VEGF antibodies with human VEGF is 10<-9>-10<-11>M. According to the invention, identification on immunocompetence and biological activity of the antibody is completed, the anti-VEGF antibody is verified to have the characteristic of being antagonistic to combination of VEGF and VEGFR2 and can effectively inhibit proliferation of vascular endothelial cells induced by VEGF. The invention provides a new specific candidate antibody molecule for resisting tumour and senile macular degeneration targeted by VEGF in future.

The invention belongs to the field of antibody drug, and discloses a full human-derived anti-human VEGFR2 monoclonal antibody screened by a phage antibody base technology and prepared by a gene engineering method, and further discloses a carrier including polynucleotide for encoding the monoclonal antibody, a host cell and an application. Through combining with VEGFR2, the monoclonal antibody stops the combination of VEGF with VEGR2, and does not induce receptor dimerization, cause the following tyrosine residue phosphorylation in intracellular tyrosine kinase structure and activate downstream signal access including activation of phospholipase C and increase of calcium ion concentration in the cell and others; the antibody drug triggers endothelial proliferation, survival, cytoskeleton rearrangement, cell migration, gene expression and others, and finally stops the vascular proliferation caused by combination of VEGF and VEGFR2 and induction of dimerization. The monoclonal antibody can be used for treating diseases caused by tumor angiogenesis.

The invention discloses an application of calycosin in radix astragali in preparing a medicament for vascular protection. Angiogenesis is promoted by vascular endothelial cell proliferation, , and further a good vascular protection effect is generated; the prepared medicament used as a selective estrogen modulator can replace estrogen, promote the angiogenesis, and protect the vascular endothelialcells, thereby treating cardiovascular diseases (such as atherogenesis and the like).

The invention discloses an experimental method for promoting tissue engineering pre-vascularization by umbilical cord mesenchymal stem cells; according to the method, vascular endothelial cells and umbilical cord mesenchymal stem cells with different proportions are co-cultured in a two-dimensional manner, and a rule of promoting vascular endothelial cell proliferation and hematopoietic differentiation by the umbilical cord mesenchymal stem cells is studied. In addition, a micron-sized network microvascular scaffold is prepared by high temperature molten monosaccharide and is dissolved in hydrogel to construct a continuous microchannel culture system of a three-dimensional hydrogel female die, the two cells are subjected to perfusion and suspension culture, an in-vitro constructed microvascular network structure and an engineered bone tissue in-vivo transplantation effect based on the structure are evaluated, and a mechanism of the two cells participating and promoting microvascular network construction is illuminated. A new solution and an experimental basis are provided for in-vitro pre-vascularization of engineered tissues and organs.

The invention belongs to the technical field of biomedicine, in particular to the technical field of an albumin medicament. In order to solve the technical problems of short half-life period in vivo and high use level of the existing ATWLPPR peptide, the invention provides an albumin variant. The albumin variant is obtained by mutating a KEQLK peptide section at the tail end of albumin C to a WLPPR peptide section. The albumin variant completely reserves the functions of human albumin and simultaneously has a new ATWLPPR sequence function. Experiments in vitro prove that the albumin variant can obviously inhibit the proliferation and migration of vascular endothelial cells induced by VEGF (Vascular Endothelial Growth Factor) in vitro, and the efficiency of the albumin variant corresponds to that of small peptide. Moreover, when the albumin variant is injected into animals, the efficiency of inhibiting the cornea angiogenesis functions of rabbits is 40-60 times higher than that of the small peptide with the same concentration. The albumin variant can be used as a novel anti-angiogenesis medicament with high efficiency.

An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein.

A DNA composition effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor polypeptide, which can be a full length VEGF receptor protein or an immunogenic fragment thereof. This invention provides DNA compositions that encode VEGF receptor-2 (KDR), VEGF receptor-1 (Flt-1), or Flk-1 (the murine homolog of KDR), as well as methods of using such a DNA composition to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved.

The invention relates to functional self-assembling nano peptide hydrogel (RADA16-I / KLT / RGD) which can promote cell adhesion and can promote vascular endothelial cell proliferation and migration. The functional self-assembling nano peptide hydrogel comprises ion complementary type self-assembling nano peptide RADA16-I, KLT function peptide containing VEGF (vascular endothelial growth factor) mimetic peptide fragments and RGD function peptide containing RGD short peptide sequences. The functional self-assembling nano peptide hydrogel can promote cell adhesion, can promote vascular endothelial cell proliferation and migration, is a good tissue engineering framework material, and can be used for scientific research of tissue engineering technology or cytobiology and the like. The invention further provides physical characteristics, a preparation method and an application of the functional self-assembling nano peptide hydrogel.

The invention provides a preparation device and a preparation method for a small-caliber artificial blood vessel micropore structure, and belongs to the technical field of artificial blood vessels. The preparation device is composed of a small-caliber artificial blood vessel preparation device and a micropore preparation device. The small-caliber artificial blood vessel preparation device includesa fixed bracket, a motor, a round tube mold, a heating device, a lifting platform and a dripping device. The micropore preparation device comprises an air pump, a flow valve, a connecting tube, a spray barrel, a second connecting rod and a second clamp. The invention also provides a method for preparing the small-caliber artificial blood vessel micropore structure by the device. The device and method are suitable for all high-molecular materials which are soluble in an organic solvent having a boiling point lower than 160 DEG C, and small-caliber artificial blood vessels of different micropores and specific surface areas can be prepared through the adjustment of conditions such as particle type, size, gas blasting rate and centrifugal force. According to the preparation device and the preparation method, the small-caliber artificial blood vessel with the micropore structure has a function of being favorable for vascular endothelial cell proliferation.